GERN – geron corporation (US:NASDAQ)
Stock Stats
News
4/14
04:11 pm
gern
Low
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers - GERN
4/14
09:01 am
gern
Medium
GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm
4/12
10:53 am
gern
Medium
Geron Corporation (GERN) Investors: May 12, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
4/11
02:55 pm
gern
Low
GERN Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Geron Corporation (GERN)
4/11
05:45 am
gern
High
Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN
2/26/2025
07:30 am
gern
-33.2%
MISS
2/26/2025
07:30 am
gern
-33.2%
MISS
2/26/2025
07:30 am
gern
-31.5%
MISS
2/26/2025
07:30 am
gern
-31.2%
MISS
3/12
08:05 am
Reiterates
Neutral
Neutral
HC Wainwright
Medium
9.3%
3/12
08:05 am
Reiterates
Buy
Buy
Needham & Company LLC
Medium
9.3%
3/12
07:22 am
Reiterates
Buy
Buy
Needham
Medium
7.9%
3/12
07:22 am
Reiterates
Buy
Buy
Needham
Medium
7.9%
2/27
01:05 pm
Maintains
Sector Outperform
Sector Outperform
Scotiabank
Low
-0.9%
4/8
04:16 pm
gern
Medium
Form ARS GERON CORP For: Dec 31
4/8
04:11 pm
gern
Medium
Form DEFA14A GERON CORP
4/8
04:06 pm
gern
Medium
Form DEF 14A GERON CORP For: May 21
4/2
05:30 pm
gern
Medium
Form 4 GERON CORP For: Mar 31 Filed by: Spiegel Robert J.
4/2
05:10 pm
gern
Medium
Form 4/A GERON CORP For: Dec 31 Filed by: Spiegel Robert J.
Show more
Top News Gainers
9/30 Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis 13.6%
3/17 Geron Co. (NASDAQ: GERN) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock. 10.5%
3/19 GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm 10.2%
3/20 Geron Co. (NASDAQ: GERN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 8.9%
10/10 Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 7.0%
1/13 Form 4 GERON CORP For: Jan 10 Filed by: O'Farrell Elizabeth G. 6.7%
3/12 Q4/2019 12/31/2019 EPS -0.150 ZacksConsensus -0.200 ActVsEst 0.050 - Beat 6.5%
8/15 Geron Co. (NASDAQ: GERN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 6.1%
8/8 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 5.8%
3/20 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm 5.8%
Top News Decliners
5/16 Geron Provides Imetelstat Program Update -9.8%
3/5 Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -9.7%
9/3 Geron Co. (NASDAQ: GERN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -7.6%
3/15 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm -7.3%
6/17 Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress -6.4%
11/15 Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT [Yahoo! Finance News] -5.1%
8/22 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.9%
12/19 Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -4.7%
10/17 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.7%
1/30 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation (GERN) -4.4%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3